Diets · Metabolic & Cardiometabolic
Does very high cholesterol on low-carb diets still clog arteries?
The claim, precisely: lean mass hyper-responder phenotype causes coronary atherosclerosis progression
Yes — high "bad" cholesterol raises plaque risk however it got high; the popular claim that this pattern is uniquely safe isn't supported.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Whether the extreme LDL/ApoB of the LMHR phenotype causes coronary plaque is UNRESOLVED and the honest crux. The general ApoB->atherosclerosis causal chain is rock-solid, but LMHR-specific outcome data are thin and conflicted. CRITICAL: the flagship longitudinal study claiming 'plaque predicts plaque, ApoB does not' ([[ketocta-longitudinal-2025-RETRACTED]], PMID 40192608) was RETRACTED in 2026 ([[
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Houttu 2023 · Nutrients | observational | supports | moderate | Critical review: high-fat low-carb diets can induce severe FH-mimicking LDL elevations; cautions these warrant clinical attention given LDL-ASCVD causality. |
| Ference 2012 2012 · J Am Coll Cardiol | observational | supports | high | Mendelian randomization: lifelong lower LDL via LDL-lowering alleles gave ~3x the CHD risk reduction per mmol/L vs late statin therapy; cumulative-exposure causality. |
| Ference 2017 · European Heart Journal | meta-analysis | supports | high | EAS consensus: genetic, epidemiologic & RCT evidence that LDL causally drives ASCVD in a log-linear, cumulative-exposure manner (supports premise LMHR LDL is atherogenic). |
| Soffer 2024 · J Clin Lipidology | observational | supports | high | NLA consensus: apoB (atherogenic particle count) superior to LDL-C for ASCVD risk; LMHR's high apoB implies elevated long-term risk. |
| Norwitz NG, Feldman D, Soto-Mota A 2026 · Diseases | observational | contradicts | low | Case report (n=1): LDL ~700 for 7y, no coronary atherosclerosis reported |
| Budoff M, ... Norwitz NG, et al. (KETO Trial) 2024 · JACC Adv | observational | tested-null | low | KETO Trial CTA: plaque correlated with BASELINE plaque, not with keto-LDL (cross-sectional, n~80, no control) |
| Nicholls 2018 · J Am Coll Cardiol | RCT | supports | high | Evolocumab substudy: very low LDL-C shifted plaque toward regression/stabilized composition; reinforces causal LDL->coronary plaque link underpinning the LMHR concern. |
| Nicholls 2016 · JAMA | RCT | supports | high | GLAGOV RCT/IVUS: incremental LDL-C lowering with evolocumab caused coronary atheroma regression proportional to achieved LDL; LDL drives plaque progression. |
| Norwitz NG, Soto-Mota A, et al. 2022 · Front Endocrinol | observational | contradicts | low | Case report (n=1): LDL to 545 mg/dL >2y, CT angiography showed no plaque |
| Norwitz NG, et al. 2022 · J Clin Lipidol | observational | mixed | low | LMHR-network letter: flags markedly elevated LDL in LMHR as deserving urgent attention/further research; acknowledges outcome data lacking. |
| Glavinovic 2022 · J Am Heart Assoc | mechanism | supports | moderate | Physiologic basis for apoB superiority: total apoB-particle number governs atherogenic risk independent of cholesterol-per-particle; relevant to LMHR particle burden. |
| Boren 2020 · European Heart Journal | meta-analysis | supports | high | EAS pathophysiology consensus: LDL particles cause atherosclerosis via subendothelial retention; total apoB-particle burden is the causal driver. |
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.